Patents Assigned to The United States of America as represented by the Secretary of the Department of Veterans Affairs
-
Publication number: 20190059718Abstract: The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.Type: ApplicationFiled: March 26, 2018Publication date: February 28, 2019Applicants: University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans AffairInventors: Michael D. Abramoff, Meindert Niemeijer, Xiayu Xu, Milan Sonka, Joseph M. Reinhardt
-
Patent number: 10137136Abstract: In one aspect, the invention relates to methods for treating muscle atrophy by providing to an animal in need thereof an effective amount of a compound. The compound can modulate the expression levels of multiple mRNA of a muscle atrophy signature. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: February 23, 2016Date of Patent: November 27, 2018Assignees: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRSInventors: Christopher M. Adams, Steven D. Kunkel, Michael Welsh
-
Patent number: 10034936Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.Type: GrantFiled: August 15, 2014Date of Patent: July 31, 2018Assignees: The University of Iowa Research Foundation, The United States of America as represented by the Secretary of the Department of Veterans AffairsInventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
-
Publication number: 20180118657Abstract: In one aspect, the invention relates methods for inhibiting or preventing muscle atrophy or increasing muscle mass by providing to a subject in need thereof an effective amount of ursolic acid, a derivative thereof, or an analog of the ursane scaffold. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: November 6, 2017Publication date: May 3, 2018Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF VETERANS AFFAIRSInventors: Christopher M. ADAMS, Steven D. KUNKEL, Manish SUNEJA, Michael WELSH
-
Patent number: 9924867Abstract: The methods and systems provided can automatically determine an Arteriolar-to-Venular diameter Ratio, AVR, in blood vessels, such as retinal blood vessels and other blood vessels in vertebrates. The AVR is an important predictor of increases in the risk for stroke, cerebral atrophy, cognitive decline, and myocardial infarct.Type: GrantFiled: January 20, 2012Date of Patent: March 27, 2018Assignees: University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans AffairsInventors: Michael D. Abramoff, Melndert Niemeijer, Xiayu Xu, Milan Sonka, Joseph M. Reinhardt
-
Patent number: 9790267Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.Type: GrantFiled: February 17, 2014Date of Patent: October 17, 2017Assignees: The Trustees of the University of Pennsylvania, The United States of America, as represented by the Secretary of the Department of Veterans AffairsInventor: David Kaplan
-
Patent number: 8870786Abstract: Methods, articles of manufacture, and systems for evaluating tinnitus are disclosed herein. According to various embodiments, a tinnitus evaluation system may include a tinnitus evaluation module configured to perform one or more tinnitus evaluation tests. A tinnitus evaluation test may comprise generating a first single-frequency sound based at least in part on a sound of a patient's tinnitus, and generating a narrow-band sound centered at the frequency of the first single-frequency sound. Tests include a hearing threshold test, a loudness match test, a pitch match test, a bandwidth match test, a minimum masking level test, and a residual inhibition test.Type: GrantFiled: January 14, 2013Date of Patent: October 28, 2014Assignees: Oregon Health & Science University, The United States of America as represented by the Secretary of The Department of Veterans AffairsInventors: James A. Henry, Grayson Silaski, David Gray, Edward V. Porsov, Kimberly Owens
-
Patent number: 8858946Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.Type: GrantFiled: July 24, 2008Date of Patent: October 14, 2014Assignees: The University of Iowa Research Foundation, The United States of America, as represented by the Secretary of the Department of Veterans AffairsInventors: Jack T. Stapleton, Jinhua Xiang, Donna Klinzman, James H. McLinden
-
Patent number: 7807458Abstract: Described herein are post natal, multilineage inducible cells (MIAMI cells). In some examples, the cells are isolated from non fractionated, adult (males and females 3 to 72 years old) human bone marrow under cell culture conditions, which are believed to resemble an in vivo niche microenvironment in which primitive multipotent cells exist. MIAMI cells have a unique profile of molecular markers, and can be maintained in vitro (for more than 50 population doublings) without detectable changes in their characteristic molecular profile. MIAMI cells can be differentiated into mesodermal, neuroectodermal, and endodermal cell lineages. Methods of isolating, differentiating and using MIAMI cells are also described.Type: GrantFiled: January 29, 2004Date of Patent: October 5, 2010Assignees: The United States of America as represented by the Secretary of the Department of Veterans Affairs, The University of MiamiInventors: Paul C. Schiller, Gianluca D'Ippolito
-
Patent number: 7361493Abstract: Embodiments of a method for the production of human urokinase are disclosed. Also disclosed are embodiments of a cell culture well-suited for use with the disclosed method. The method involves culturing urokinase-producing cells, such as immortalized human renal cells, in a cell culture. The cell culture comprises microcarrier structures and a tissue culture medium. The urokinase production is allowed to occur while the cell culture remains relatively static, i.e., the cell culture is not substantially mixed.Type: GrantFiled: May 26, 2005Date of Patent: April 22, 2008Assignees: The United States of America as represented by the Secretary of the Department of Veterans Affairs, Tulane UniversityInventors: Timothy G. Hammond, Patricia L. Allen
-
Patent number: 7202030Abstract: This invention relates to the enzymatic synthesis of oligophenols on solid support by sequential enzymatic addition of reaction solutions containing phenols. The oligomers are then selectively built up on the solid surface. When used in a specific format, the oligomers can be generated in a spatially addressable array, which can then be screened for some type of biological interaction. The synthetic compounds of the present invention are synthesized in a combinatorial manner on solid support using peroxidase or other related enzymatic catalysis, and the products are generated in spatially addressable microarrays. Oligophenols of the present invention have shown significance as potential inhibitors of NADPH oxidase assembly, an enzyme that has been implicated in a wide range of diseases stemming from vascular hyperpermeability.Type: GrantFiled: November 1, 2002Date of Patent: April 10, 2007Assignees: Rensselaer Polytechnic Institute, The United States of America as represented by the Secretary, Department of Veterans AffairsInventors: Jonathan S. Dordick, Lakshmi Santhanam, Michael G. Hogg, James A. Holland